Leadership

BARD1 has an experienced board and management team with a track record in building successful companies, and international expertise in BARD1 biology, biomarker translation and respiratory medicine.

Peter Gunzburg BCom | Executive Chairman

Peter Gunzburg is a public company director, stockbroker and technology investor, with over 20 years corporate advisory, capital raising, transaction and business management experience. Peter has previously been a director of Resolute Ltd, Australian Stock Exchange Ltd, Eyres Reed Ltd, CIBC World Markets Australia Ltd, Fleetwood Corporation Ltd and Dragon Mining Ltd.


Dr Irmgard Irminger-Finger PD PhD | Executive Director & Chief Scientific Officer

Dr Irminger-Finger is founder and co-inventor of BARD1 and its technology. She has more than 15 years of experience in biotech as founder, director, and chair, as recipient of Swiss start up awards, and as one of five finalists of the 2014 European Woman Entrepreneur Award. She is an internationally recognised expert in tumor biology with over 100 publications, multiple international collaborations and many keynote presentations at international conferences. Irmgard has a Masters degree in molecular biology and a PhD in molecular genetics from the University of Zurich, and was an award research fellow at the Harvard University. She holds a tenured faculty position at the University (UNIGE) and University Hospital of Geneva (HUG) and Adjunct Professorship at the University of Western Australia (UWA).


Max Johnston | Non-Executive Director (appointed 17 June 2019)

Mr Max Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the world’s largest medical, pharmaceutical and consumer healthcare company for 11 years. Prior to joining Johnson & Johnson, Mr Johnston’s career also included senior roles with Diageo and Unilever in Australia, Africa and Europe. Mr Johnston has also held several prominent industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of ASMI. Mr Johnston has had extensive overseas experience during his career in leading businesses in both Western and Central-Eastern Europe and Africa as well as the Asia-Pacific region. Mr Johnston is currently a Non-Executive Director of PolyNovo Ltd (ASX: PNV), Medical Developments International Ltd (ASX: MVP), CannPal Limited (ASX: CP1) and ProLife Foods NZ and was a former Non-Executive Director of Enero Group Limited (ASX: EGG) and Non-Executive Chairman of Probiotec Ltd (ASX: PBP).


Philip Powell | Non-Executive Director (appointed 17 June 2019)

Mr Philip Powell is a Chartered Accountant with extensive experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney and Los Angeles. Mr Powell is currently a Non-Executive Director of PolyNovo Ltd (ASX: PNV), Medical Developments International Ltd (ASX: MVP). and RMA Global Ltd (ASX: RMY). He is also an alternate Director of the Nature’s Dairy Australia group.


Dr Leearne Hinch BSc BVMS MBA | Chief Executive Officer

Dr Leearne Hinch is a biotechnology executive and consultant with extensive experience in the life science industry in general management, strategy, fundraising, business development and commercialisation. Leearne has strategic, operational and technical experience leading and managing the development and commercialisation of drug, device and animal health products. She is director of commercialisation advisory Ingeneus Solutions, and previously held CEO and executive positions in ASX-listed biotechnology, multinational and private companies including Eustralis Pharmaceuticals Ltd, Immuron Ltd, OBJ Ltd, Holista CollTech Ltd, Chemeq Ltd and Virbac (Australia) Pty Ltd.